1. America’s Health Insurance Plans. 2015. Specialty drugs: Issues and challenges. https://www.ahip.org/wp-content/uploads/2015/07/IssueBrief_SpecialtyDrugs_7.9.15.pdf. Accessed December 30, 2019.
2. Australian Institute of Health and Welfare. 2018. Australia’s health. https://www.aihw.gov.au/getmedia/7c42913d-295f-4bc9-9c24-4e44eff4a04a/aihw-aus-221.pdf.aspx?inline=true. Accessed December 30, 2019.
3. Batt, S., J. Butler, O. Shannon, and A. Fugh-Berman. 2020. Pharmaceutical ethics and grassroots activism in the United States: A social history perspective. Journal of Bioethical Inquiry 17(1).
4. Boulanger, R.F., A. Komparic, A. Dawson, R.E.G. Upshur, and D.S. Silva. 2020. Developing and implementing new TB technologies: Key informants’ perspectives on the ethical challenges. Journal of Bioethical Inquiry 17(1).
5. Community Affairs Reference Committee. 2015. Report: Availability of new, innovative and specialist cancer drugs in Australia. https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/Cancer_Drugs/Report. Accessed December 30, 2019.